Quadrant Capital Group’s BioNTech BNTX Stock Holding History

Quadrant Capital Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,054	Closed	-$183K	–	1428
2026 Q1	$183K	Buy	+2,054	New	+$211K	0.01%	1293
2024 Q3	–	Sell	-806	Closed	-$64.8K	–	2743
2024 Q2	$64.8K	Hold	806	–	–	﹤0.01%	1268
2024 Q1	$74.4K	Sell	806 -4	-0.5%	-$384	0.01%	1157
2023 Q4	$85.5K	Buy	+810	New	+$81.6K	0.01%	1088

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Quadrant Capital Group's BNTX Position: Q2 2026 in Review

Quadrant Capital Group sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 2,054 shares — an estimated $183K sold.

Quadrant Capital Group first reported a position in BNTX in Q4 2023 and held it in 4 quarters. The position peaked at $183K in Q1 2026. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Quadrant Capital Group reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 2,054 BioNTech shares in Q2 2026, an estimated $183K.
Quadrant Capital Group first reported a position in BioNTech in Q4 2023 and held it in 4 quarters.
Quadrant Capital Group's BioNTech position peaked at $183K in Q1 2026.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.